FDA Inspection 1327050 — Cai'e Wang
The FDA completed an inspection of Cai'e Wang on Jun 25, 2026 in Luoyang. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Jun 25, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Luoyang (China)
Additional Details
Clinical BA/BE